 NEW YORK, Sept. 23, 2021 GLOBE NEWSWIRE -- Brooklyn ImmunoTherapeutics, Inc. NYSE American: BTX Brooklyn, a biopharmaceutical company focused on exploring the role that cytokine and gene editingcell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that on September 20, 2021, Roger Sidhu was granted a non-qualified stock option covering 161,300 shares of Brooklyns common stock the Time-Based Option and a restricted stock unit covering 80,650 shares of Brooklyns common stock the RSU. 